Flush With Cash, Tesaro Advances Rolapitant Toward NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.